Abstract
This study examines platelet adhesion on surfaces that combine coatings to limit protein adsorption along with "anti-platelet" nitric oxide (NO) release. Uncoated and poly-2-methoxyethylacrylate (PMEA) coated, gas permeable polypropylene (PP) membranes were placed in a bioreactor to separate plasma and gas flows. Nitrogen with 100/500/1000 ppm of NO was supplied to the gas side as a proof of concept. On the plasma side, platelet rich plasma (PRP, 1x108 cell/mL) was recirculated at low (60)/high (300) flows (ml/min). After 8 hours, adsorbed platelets on PP was quantified via a lactate dehydrogenase assay. Compared to plain PP, the PMEA coating alone reduced adsorption by 17.4±9.2% and 29.6±16.6% at low and high flow (p<0.05), respectively. NO was more effective at low plasma flow. At 100 and 500 ppm of NO, adsorption fell by 37.9±6.1% and 100±4.7%, (p<0.001), on plain PP. At high flow with 100, 500, and 1000 ppm of NO, adsorption reduced by 17.9±17.8%, 46.4±23.2%, and 100±4.8%, (p<0.001), respectively. On PMEA-coated PP with only 100 ppm, adsorption fell by 69.7±6.8 and 65.6%±16.9%, (p< 0.001), at low and high flows respectively. Therefore, the combination of an anti-adsorptive coating with NO has great potential to reduce platelet adhesion and coagulation at biomaterial surfaces.
Introduction
Various artificial organs, catheters, stents, and other medical devices operate under long-term blood contact. Protein adsorption and platelet activation on the surfaces of these devices lead to clot formation. This, in turn, causes device failure and thromboembolic complications. The most common solution to this problem is systemic anticoagulation, but this leads to bleeding complications that can also contribute to patient morbidity and mortality. [1] [2] [3] Anticoagulation that is limited only upon device surfaces could remedy these shortcomings.
Two methods of surface focused anticoagulation have demonstrated some promise in reducing coagulation: surface coatings designed to limit nonspecific protein adsorption and antiplatelet surface NO release. Surface coatings only reduce coagulation in the device and thus have no systemic anticoagulant effect. Various commercial anti-thrombogenic coatings have shown better preservation of platelet counts than the uncoated control surface [4, 5] during short -1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 term applications. However, these surface coatings have not yet proven sufficient to allow the elimination of systemic anticoagulation or long-term use of high surface area artificial organs without significant decrease in systemic platelet concentration. [6, 7] Nitric oxide is released from biomaterials into flowing blood, [8] [9] [10] [11] [12] but has a short half-life of 2-5 seconds [8] in blood prior to being scavenged. Thus, its systemic effects are minor, and it has been examined as a means to focus anticoagulation at biomaterials' surfaces rather than systemically. Several means of supplying surface NO flux have been tested. They include NO release from a stored pool in the biomaterial, NO generation from endogenous sources in blood, and NO delivery via the gas flow in artificial lungs. [9 -12] Early studies examining the latter approach were largely unsuccessful. These studies did not quantify surface NO flux, and it was likely insufficient. [13] More recent studies with proven, endothelial levels of NO flux (> 2x10 -10 mol/min/cm 2 ) have been successful, reducing platelet adhesion in tubing and catheters by approximately 40%, [9, 10] and markedly reducing coagulation and increasing longevity in artificial lungs. [12] Although positive, these studies were all for a period of 4 hours. Longer-term effectiveness in these settings is unknown. Additionally, use of NO in high surface area artificial organs could lead to excessive generation of methemoglobin in the blood, limiting the possible flux rates, and anticoagulation.
In this study, we hypothesize that the combination of anti-adsorptive coatings and surface NO flux will lead to more effective surface-focused anticoagulation. Anti-adsorptive coatings would limit protein adsorption, thereby reducing platelet activation induced via surface adhesion or surface-generation of agonists. In theory, a lower level of NO could then be used to anesthetize the limited number of platelets that adhere to the surface or contact the lower levels of soluble agonists. In this way, the surface would operate more like the endothelium, which uses several simultaneous methods to control coagulation. [14 -16] To examine this hypothesis, bioreactors were constructed with gas permeable polypropylene membranes. The bioreactors were then used to determine the relationship between sweep gas concentration and NO flux. Platelet rich plasma was recirculated over polypropylene membranes that were either uncoated or coated with PMEA. Various levels of NO Twenty-five milimeters of this mixture was injected into each of the three bioreactors.
Each bioreactor was fitted with a 3'' x 0.5'' gas permeable PP membrane with an average pore 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 was then sectioned lengthwise into two halves. One half was assayed for LDH, and the other half was fixed for SEM analysis (see sections 3.6 and 3.7). Experimental runs with three circuits were repeated until five experiments were performed for each coating, NO concentration, and PRP flow rate combination.
Lactate Dehydrogenase (LDH) Assay
A lactate dehydrogenase (LDH) assay kit (Cayman Chemicals Ann Arbor, 10008882) was used to quantify platelets adhered on the surface of each membrane after 8 hours of PRP exposure in the bioreactor. Each membrane section was incubated at 37ºC in two mL of lysing reagent (1% Triton-X100, 0.75% Bovine Albumin Serum in phosphate buffered saline) for 1hr, with occasional agitation. The suspension was then assayed for LDH according to the kit manufacturer's protocol. , and 7.5x10 6 cell/ml and were assayed for LDH. A linear curve fit was then used to determine the relationship between absorbance from LDH and number of cells. This curve was found to be LDH absorbance = 0.12 x platelets (x10 6 cells/mL) + 0.01, (R 2 = 0.99).
SEM Analysis
One half of each tested membrane was fixed with 2% gluteraldehyde (Sigma Aldrich, ST Louis MO) overnight and then dehydrated in a series of ethanol solutions and completely dried. The mid-section of the membrane was cut, sputter-coated with gold, and imaged by a Hitachi S-3200N scanning electron microscope (15 kV).
Data and Statistical Analysis
Raw LDH data obtained from coated and uncoated samples were adjusted to remove background LDH levels. To do so, a control study was run using PBS only in the circuit and assaying these membranes for LDH in the described manner (n=4). The average background 
Results
Nitric oxide concentration in water over time exhibited the characteristic curve shown in Figure 3 .
The gas' concentration in water steadily increased during recirculation of PBS and flow of NO 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 This suggests two things. First, NO should be more effective in stagnant regions where clots typical form in medical devices. Local Peclet numbers will be small, nitric oxide will accumulate, and this should have a greater effect than local procoagulant accumulation. Second, NO will be less effective in whole blood. At the same Reynolds number, the Peclet number will be larger because of 1) higher blood viscosity (≈ 4x water) and 2) a smaller effective NO diffusivity due to NO scavenging by red blood cells (RBCs). [20] The extent of this effect, however, will vary from application to application. In all situations, there will be a cell-free, exclusionary layer near the surface that contains only platelet rich plasma, which may moderate the effect of RBCs. The thickness of this zone in laminar flows is on the order of the RBC diameter, 8 μm, but will varies with local fluid mechanics. [21] [22] [23] Further studies are thus necessary to examine the effect of RBCs on NO inhibition of platelets in various whole blood flow conditions.
Several other limitations should be considered in the interpretation of these results. First, the test system was a closed in-vitro circuit. Thus, both NO concentration and surface-generated procoagulant molecules accumulate over time. If used in-vivo with whole blood, such accumulation would not occur due to RBC binding and by clearance of procoagulant molecules.
Second, NO delivery was provided in this study via diffusion from an N 2 and NO mixture.
This served as a relatively simple means to approximate NO release from NO donors in polymers [24] and estimate NO fluxes. However, as mentioned previously, NO flux rates and local concentrations will be different in blood due to the presence of NO scavengers. Furthermore, the effect of NO will vary slightly if NO is catalytically generated from donors in blood [25] , or if NO is mixed with O 2 immediately prior to delivery to artificial lungs. In the former case, the effect of local flow rate will be different, as increased flow rate will also increase transport of NO donors to the polymer surface. In the latter, NO will be transported in part as nitrite or nitrate, which could reduce platelet inhibition.
On the positive side, this technique could be attempted with other polymer coatings.
PMEA has been determined to be the most effective anti-protein coating of the acrylate polymers, but it's also one of many low-fouling polymers available [26] . Another, promising type of non -1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 fouling coating are those composed of zwitterionic polymers. This class of polymers demonstrates far lower protein adsorption (<0.3 pg/cm 2 ) after incubation with 100% plasma and whole blood under static conditions [27 -36] . Protein adsorption on PMEA coatings, however, has been reported as 300 pg/cm 2 [37] . Thus, zwitterionic coatings may prove even more effective when combined with NO, allowing for even greater platelet inhibition at low NO concentrations. This, in turn, would help avoid the metHb generation by nitric oxide.
Conclusion
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